Pesquisar um medicamento órfão
Outras opções de pesquisa
Designação órfã retirada - Europa
- Nome de comercialização: KIOVIG
- Código ATC: J06BA02
- Número EU: EU/1/05/329/...
- Data da MA: 19/01/2006
- Detentor da MA: BAXTER AG
- Relatório Público Europeu de Avaliação (EPAR)
Therapeutic indication
*Replacement therapy in adults, and children and adolescents (0-18 years) in:
- Primary immunodeficiency syndromes with impaired antibody production,
- Hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic leukaemia, in whom prophylactic antibiotics have failed,
- Hypogammaglobulinaemia and recurrent bacterial infections in plateau phase multiple myeloma patients who have failed to respond to pneumococcal immunisation,
- Hypogammaglobulinaemia in patients after allogeneic haematopoietic stem cell transplantation (HSCT).
*Immunomodulation in adults, and children and adolescents (0-18 years) in:
- Primary immune thrombocytopenia (ITP), in patients at high risk of bleeding or prior to surgery to correct the platelet count,
- Guillain Barré syndrome,
- Kawasaki disease,
- Multifocal Motor Neuropathy (MMN).
Lista de doenças
- Doença de Kawasaki
- Imunodeficiência afetando predominantemente a produção de anticorpos
- Neuropatia motora multifocal com bloqueio de condução
- Síndrome Evans
- Síndrome Guillain-Barré
- Trombocitopénica imune